National Registry of IgG4-Related Disease in China

What this Trial Is About

Researchers are establishing a nationwide registry study to gather detailed information about IgG4-related disease (IgG4-RD) patients in China. The study aims to better understand the disease's clinical features, demographics, lab and immunological characteristics, imaging, pathology, treatment, and prognosis. The study includes patients who meet the 2011 diagnostic criteria for IgG4-RD and excludes those with malignancies or other autoimmune diseases. Patients newly diagnosed with IgG4-RD will be enrolled from multiple centers across China. Data will be collected through an online system, including demographic details, symptoms, disease duration, allergy history, physical exams, organ involvement, lab results, imaging, pathology, treatments, and side effects. The study has ethical approval, and participants will provide informed consent. Participants will be followed for several years to assess organ involvement, responses to glucocorticoids and immunosuppressants, relapse rates, tumor incidence, survival rates, imaging features, and pathological diagnosis accuracy. Data analysis will be conducted using standard statistical methods, with a focus on long-term outcomes and disease behavior. The total follow-up period extends up to ten years for survival analysis.

National Registry of IgG4-RD in China